News Releases

News and information from The Leukemia & Lymphoma Society

Immunotherapy Study Funded by The Leukemia & Lymphoma Society Demonstrates Remarkable Results in Patients with Acute Lymphoblastic Leukemia

Contact: Andrea Greif
(914) 821-8958 White Plains, NY (October 16, 2014) - Funding from The Leukemia & Lymphoma Society (LLS) over the past 22 years helped advance a study published today in the New England Journal of Medicine showing that 90 percent of children and adults with acute lymphoblastic leukemia (ALL) achieved complete remission after receiving an investigatio...

Aptose Biosciences Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML Research Initiative With Oregon Health & Science University

Contact: Andrea Greif, Senior Director of Communications 
The Leukemia & Lymphoma Society
914-821-8958 SAN DIEGO, CALIFORNIA and TORONTO, CANADA; PORTLAND, OREGON; WHITE PLAINS, NEW YORK - September 29, 2014 - Aptose Biosciences Inc. (TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechan...

Louis J. DeGennaro, Ph.D., Named President and Chief Executive Officer of The Leukemia & Lymphoma Society

Contact: Andrea Greif
(914) 821-8958 White Plains, NY (September 9, 2014) - The Leukemia & Lymphoma Society (LLS) announced today that Louis J. DeGennaro, Ph.D., has been appointed as president and chief executive officer, effective immediately. "Dr. DeGennaro has tirelessly dedicated himself for almost a decade of service to the LLS mission and to the patients whom w...

The Leukemia & Lymphoma Society Provides Equity Financing to OncoPep to Support Clinical Trial for Myeloma Vaccine

Contact: Andrea Greif
(914) 821-8958 White Plains, NY (Aug. 28, 2014) - The Leukemia & Lymphoma Society (LLS) and OncoPep have entered a partnership to advance an experimental cancer vaccine to treat patients with smoldering multiple myeloma (SMM), an asymptomatic stage of myeloma. The partnership is through LLS's Therapy Acceleration Program® (TAP), through which LL...

Five Things You Need To Know About Blood Cancers And One Thing You Can Do

Contact: Marcie Klein
(914) 821-8205 White Plains, NY (August 27, 2014) - Every three minutes, someone in the U.S. is diagnosed.  More than 1.1 million Americans are living with, or in remission from, these diseases. Certain forms of these diseases are the most common types of cancer in children and adolescents younger than 20 years. Almost 150,000 Americans will be dia...

The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers

(White Plains, NY) - July 23, 2014 - Today's U.S. Food and Drug Administration (FDA) approval of idelalisib to treat patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) is a significant advance for patients with these blood cancers.  
Idelalisib, which goes by the trade name Zydelig (R), is a first-in-class inhibi...

Record-Breaking Year for the Leukemia & Lymphoma Society's Man & Woman of the Year Campaign

Contact: Kristin Hoose
(914) 821-8973 White Plains, NY (July 17, 2014) - A Chicago man and Los Angeles woman raised $386,284 and $343,962, respectively, to support The Leukemia & Lymphoma Society's (LLS) mission to find cures for blood cancers and ensure that patients have access to lifesaving treatments.  As the leading fundraisers in the 2014 Man & Woman of t...

James Davis, Biotechnology Consultant, Elected Chair of LLS National Board of Directors

For Immediate Release Contact: Andrea Greif
Tel: (914) 821-8958
Cell: (914) 772-3027 News Release  White Plains, N.Y. (July 16, 2014) - James Davis, Ph.D., JD, a consultant in crisis management and the launch of new technologies for biotechnology and other companies, has been elected chairman of the national board of directors of The Leukemia & Lymphoma...


Media Contact

Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday: